Compare
Perrigo Co PLC vs Jazz Pharmaceuticals plc vs Elanco Animal Health Inc vs Alnylam Pharmaceuticals, Inc.
| Latest fiscal year | Perrigo Co PLC PRGO | Jazz Pharmaceuticals plc JAZZ | Elanco Animal Health Inc ELAN | Alnylam Pharmaceuticals, Inc. ALNY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.25B | $4.27B | $4.71B | $3.71B |
| Revenue growth (YoY) | -2.8% | +4.9% | +6.2% | +65.2% |
| Gross margin | 35.1% | n/a | 55.0% | 81.8% (computed) |
| Operating margin | -26.4% | -10.1% | n/a | 13.5% |
| Net margin | -33.5% | -8.3% | -4.9% | 8.4% |
| Net income | -$1.43B | -$356.15M | -$232.00M | $313.75M |
| EPS (Diluted) | -$10.29 | -$5.84 | -$0.47 | $2.33 |
| Operating cash flow | $238.50M | $1.36B | $560.00M | $524.08M |
| Free cash flow | $145.10M | $1.30B | $284.00M | $465.38M |
| Cash & equivalents | n/a | $1.39B | $545.00M | $1.66B |
| Total assets | $8.54B | $11.66B | $13.36B | $4.97B |
| Total liabilities | $5.60B | n/a | $6.81B | $4.18B |
| Shareholders' equity | $2.94B | $4.32B | $6.55B | $789.18M |
| Return on year-end equity | -48.6% | -8.2% | -3.5% | 39.8% |
| Shares outstanding | 137.60M | 61.44M | 496.98M | 132.38M |
Revenue, most recent five fiscal years
| Fiscal year | Perrigo Co PLC | Jazz Pharmaceuticals plc | Elanco Animal Health Inc | Alnylam Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $4.25B Ended 2025-12-31 | $4.27B Ended 2025-12-31 | $4.71B Ended 2025-12-31 | $3.71B Ended 2025-12-31 |
| 1 year earlier | $4.37B Ended 2024-12-31 | $4.07B Ended 2024-12-31 | $4.44B Ended 2024-12-31 | $2.25B Ended 2024-12-31 |
| 2 years earlier | $4.66B Ended 2023-12-31 | $3.83B Ended 2023-12-31 | $4.42B Ended 2023-12-31 | $1.83B Ended 2023-12-31 |
| 3 years earlier | $4.45B Ended 2022-12-31 | $3.66B Ended 2022-12-31 | $4.41B Ended 2022-12-31 | $1.04B Ended 2022-12-31 |
| 4 years earlier | $4.14B Ended 2021-12-31 | $3.09B Ended 2021-12-31 | $4.76B Ended 2021-12-31 | $844.29M Ended 2021-12-31 |